Tesamorelina vs AOD-9604
Tesamorelina is mainly studied for visceral fat, body composition. while AOD-9604 is studied for body composition, lipid metabolism. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| Tesamorelina | AOD-9604 | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Studied for | Visceral fat, body composition. | Body composition, lipid metabolism. |
| How it acts | An analog studied for its relationship with the growth-hormone axis and its association with visceral-fat reduction in clinical contexts. | A fragment derived from a portion of growth hormone, studied for its relationship with lipid-metabolism pathways. |
| Evidence level | Human trials available | Preclinical evidence only |
How they differ
Although sometimes mentioned together, Tesamorelina and AOD-9604 do not target the same thing. Tesamorelina: An analog studied for its relationship with the growth-hormone axis and its association with visceral-fat reduction in clinical contexts. AOD-9604: A fragment derived from a portion of growth hormone, studied for its relationship with lipid-metabolism pathways.
See full entry: Tesamorelina → · See full entry: AOD-9604 →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between Tesamorelina and AOD-9604?
Tesamorelina targets visceral fat, body composition. and AOD-9604 targets body composition, lipid metabolism. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Tesamorelina has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Tesamorelina vs AOD-9604 or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Metabolic effects of a growth hormone-releasing factor in patients with HIVhuman N Engl J Med · 2007 · PMID 18057338 →
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionhuman J Acquir Immune Defic Syndr · 2010 · PMID 20101189 →
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab · 2010 · PMID 20554713 →
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationhuman AIDS · 2008 · PMID 18690162 →
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonepreclinical Horm Res · 2000 · PMID 11146367 →
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentpreclinical Int J Obes Relat Metab Disord · 2001 · PMID 11673763 →
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out micepreclinical Endocrinology · 2001 · PMID 11713213 →
- AOD-9604 Metabolicreview Curr Opin Investig Drugs · 2004 · PMID 15134286 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.